An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism

Jerod L. Ptacin; Carolina E. Caffaro; Lina Ma; Kristine M. San Jose Gall; Hans R. Aerni; Nicole V. Acuff; Rob W. Herman; Yelena Pavlova; Michael J. Pena; David B. Chen; Lilia K. Koriazova; Laura K. Shawver; Ingrid B. Joseph; Marcos E. Milla

doi:10.1038/s41467-021-24987-9

Nature Communications (Aug 2021)

An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism

Jerod L. Ptacin,
Carolina E. Caffaro,
Lina Ma,
Kristine M. San Jose Gall,
Hans R. Aerni,
Nicole V. Acuff,
Rob W. Herman,
Yelena Pavlova,
Michael J. Pena,
David B. Chen,
Lilia K. Koriazova,
Laura K. Shawver,
Ingrid B. Joseph,
Marcos E. Milla

Affiliations

Jerod L. Ptacin: Synthorx, Inc., a Sanofi Company
Carolina E. Caffaro: Synthorx, Inc., a Sanofi Company
Lina Ma: Synthorx, Inc., a Sanofi Company
Kristine M. San Jose Gall: Synthorx, Inc., a Sanofi Company
Hans R. Aerni: Synthorx, Inc., a Sanofi Company
Nicole V. Acuff: Synthorx, Inc., a Sanofi Company
Rob W. Herman: Synthorx, Inc., a Sanofi Company
Yelena Pavlova: Synthorx, Inc., a Sanofi Company
Michael J. Pena: Synthorx, Inc., a Sanofi Company
David B. Chen: Synthorx, Inc., a Sanofi Company
Lilia K. Koriazova: Synthorx, Inc., a Sanofi Company
Laura K. Shawver: Synthorx, Inc., a Sanofi Company
Ingrid B. Joseph: Synthorx, Inc., a Sanofi Company
Marcos E. Milla: Synthorx, Inc., a Sanofi Company

DOI: https://doi.org/10.1038/s41467-021-24987-9
Journal volume & issue: Vol. 12, no. 1
pp. 1 – 14

Abstract

Read online

The use of synthetic organisms could provide opportunities for discovery and advanced manufacturing of medical drugs. Here the authors use a semi-synthetic organism with an expanded genetic code to generate site-specific chemical modifications in human IL-2.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal